Thalidomide-induced limb defects

resolving a 50-year-old puzzle

Neil Vargesson (Corresponding Author)

Research output: Contribution to journalLiterature review

79 Citations (Scopus)

Abstract

Despite the recent discovery that thalidomide causes limb defects by targeting highly angiogenic, immature blood vessels, several challenges still remain and new ones have arisen. These include understanding the drug's species specificity, determining molecular target(s) in the endothelial cell, shedding light on the molecular basis of phocomelia and producing a form of the drug that is clinically effective without having side effects. Now that the trigger of thalidomide-induced teratogenesis has been uncovered, a framework is proposed, incorporating and uniting previous models of thalidomide action, explaining how thalidomide causes not just limb defects, but also all the other defects it induces.
Original languageEnglish
Pages (from-to)1327-1336
Number of pages10
JournalBioEssays
Volume31
Issue number12
Early online date17 Nov 2009
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Thalidomide
Extremities
Defects
Ectromelia
Teratogenesis
Species Specificity
Endothelial cells
Blood vessels
Pharmaceutical Preparations
Blood Vessels
Endothelial Cells

Keywords

  • thalidomide
  • chick limb development
  • CPS49
  • phocomelia
  • thalidomide analogue
  • therapeutics

Cite this

Thalidomide-induced limb defects : resolving a 50-year-old puzzle. / Vargesson, Neil (Corresponding Author).

In: BioEssays, Vol. 31, No. 12, 12.2009, p. 1327-1336.

Research output: Contribution to journalLiterature review

@article{d6022deb6bcc4fe787910f64068d0d83,
title = "Thalidomide-induced limb defects: resolving a 50-year-old puzzle",
abstract = "Despite the recent discovery that thalidomide causes limb defects by targeting highly angiogenic, immature blood vessels, several challenges still remain and new ones have arisen. These include understanding the drug's species specificity, determining molecular target(s) in the endothelial cell, shedding light on the molecular basis of phocomelia and producing a form of the drug that is clinically effective without having side effects. Now that the trigger of thalidomide-induced teratogenesis has been uncovered, a framework is proposed, incorporating and uniting previous models of thalidomide action, explaining how thalidomide causes not just limb defects, but also all the other defects it induces.",
keywords = "thalidomide, chick limb development, CPS49, phocomelia, thalidomide analogue, therapeutics",
author = "Neil Vargesson",
year = "2009",
month = "12",
doi = "10.1002/bies.200900103",
language = "English",
volume = "31",
pages = "1327--1336",
journal = "BioEssays",
issn = "0265-9247",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Thalidomide-induced limb defects

T2 - resolving a 50-year-old puzzle

AU - Vargesson, Neil

PY - 2009/12

Y1 - 2009/12

N2 - Despite the recent discovery that thalidomide causes limb defects by targeting highly angiogenic, immature blood vessels, several challenges still remain and new ones have arisen. These include understanding the drug's species specificity, determining molecular target(s) in the endothelial cell, shedding light on the molecular basis of phocomelia and producing a form of the drug that is clinically effective without having side effects. Now that the trigger of thalidomide-induced teratogenesis has been uncovered, a framework is proposed, incorporating and uniting previous models of thalidomide action, explaining how thalidomide causes not just limb defects, but also all the other defects it induces.

AB - Despite the recent discovery that thalidomide causes limb defects by targeting highly angiogenic, immature blood vessels, several challenges still remain and new ones have arisen. These include understanding the drug's species specificity, determining molecular target(s) in the endothelial cell, shedding light on the molecular basis of phocomelia and producing a form of the drug that is clinically effective without having side effects. Now that the trigger of thalidomide-induced teratogenesis has been uncovered, a framework is proposed, incorporating and uniting previous models of thalidomide action, explaining how thalidomide causes not just limb defects, but also all the other defects it induces.

KW - thalidomide

KW - chick limb development

KW - CPS49

KW - phocomelia

KW - thalidomide analogue

KW - therapeutics

U2 - 10.1002/bies.200900103

DO - 10.1002/bies.200900103

M3 - Literature review

VL - 31

SP - 1327

EP - 1336

JO - BioEssays

JF - BioEssays

SN - 0265-9247

IS - 12

ER -